BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors
On Wednesday, BioAffinity Technologies Inc. (NASDAQ:BIAF) announced that the US Patent and Trademark Office/USPTO has issued a new patent. The patent is titled "Compositions and Methods for Treating Cancer," and covers a novel method and composition for selectively eliminating cancer cells by targeting the CD320 and LRP2 receptors on the cell membrane.
The therapeutic approach outlined in the patent applies to a broad spectrum of cancers, including those of the lung, breast, prostate, brain, and skin. BioAffinity Technologies has already initiated research towards developing a topical treatment for skin cancers. The new patent supports the company's intellectual property portfolio, which now includes 19 awarded US and foreign patents and 36 pending patent applications related to its diagnostic platform and cancer treatment therapeutics.
A medical professional in a hospital, using targeted cancer therapuetics to treat cancer patients.
The invention utilizes small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro studies have demonstrated that the simultaneous knockdown of both proteins is selectively cytotoxic to human cancer cells, while sparing normal cells under the same treatment conditions. The studies also indicated that the double knockdown of CD320 and LRP2 is crucial, as down-regulating only one receptor led to increased protein expression in the other, and was insufficient to kill cancer cells or significantly inhibit their proliferation.
BioAffinity Technologies Inc. (NASDAQ:BIAF) develops non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the US. It operates through two segments: Diagnostic R&D and Laboratory Services.
While we acknowledge the potential of BIAF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIAF and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
13 minutes ago
- Bloomberg
Stocks to Open Flat as Trade Pact Details Awaited: Markets Wrap
Asian stocks may open with caution on Thursday as investors awaited further details on a US-China trade accord. Softer-than-expected US inflation supported the case for Federal Reserve rate cuts, spurring Treasuries higher. Asian equity futures held to muted moves early Thursday after the S&P 500 fell 0.3% Wednesday and the Nasdaq 100 dropped 0.4% as big tech weighed on US benchmarks. The declines halted a three-day advance for US stocks, with Apple Inc. down about 2%. In late hours, Oracle Corp. surged after revenue beat estimates. Contracts for US equities were little changed in early Asian trading.


Bloomberg
27 minutes ago
- Bloomberg
Bloomberg Businessweek Daily: Trump Touts China Deal
Watch Bloomberg Businessweek Daily LIVE every day on YouTube: President Donald Trump said a trade framework with China has been completed, with Beijing supplying rare earths and magnets 'UP FRONT' and the US allowing Chinese students into its colleges and universities. The US and China will maintain tariffs at their current, lower levels following the two nations' agreement this week in London, Trump said Wednesday. That number is still higher than before the president took office. Trump said Chinese President Xi Jinping and he must still formally sign off on the agreement. 'OUR DEAL WITH CHINA IS DONE, SUBJECT TO FINAL APPROVAL WITH PRESIDENT XI AND ME,' Trump posted on social media. 'WE ARE GETTING A TOTAL OF 55% TARIFFS, CHINA IS GETTING 10%. RELATIONSHIP IS EXCELLENT!' Yet after months of tense back-and-forth between Washington and Beijing, it remained unclear if the latest round of negotiations brought the two sides closer to an ultimate understanding on trade — or if it just amounted to more talk. 'Trump is mentioning the current tariff status, in a misleading way, to show he has the upper hand,' said Neo Wang, lead China macro analyst at Evercore ISI. Trump's comments prompted fresh questions about the terms of the pact US and Chinese negotiators reached Tuesday. Markets had a mixed reaction on Wednesday to comments from Trump and his team, with US equity indexes fluctuating throughout the day. Today's show features: Bloomberg Economic Chief Geoeconomics Analyst Jennifer Welch on progress in in US-China trade negotiations Alex Grassino, Global Chief Economist for Manulife Investment Management on investment options in the current economic environment Julia Coronado, Founder and President of MacroPolicy Perspectives on the US economic outlook, and expectations for US monetary policy Bloomberg Businessweek Editor Brad Stone on the LA riots and his feature story on the United States losing its moral authority across the globe

Yahoo
34 minutes ago
- Yahoo
CoreWeave reportedly a key player in Google-OpenAI partnership
-- CoreWeave is set to provide computing capacity to Google (NASDAQ:GOOGL) Cloud as part of Google's newly formed partnership with OpenAI, according to a Reuters report on Wednesday. The arrangement involves CoreWeave supplying cloud computing services built on Nvidia (NASDAQ:NVDA)'s graphics processing units to Google's cloud unit. Google will then sell this computing capacity to OpenAI to help meet the growing demand for services such as ChatGPT. In addition to CoreWeave's resources, Google will also provide some of its own computing resources to OpenAI. The deal demonstrates how the high demand for AI computing resources is creating new business alliances, even among the industry's fiercest rivals. Related articles CoreWeave reportedly a key player in Google-OpenAI partnership Dana stock surges amid $2.7 billion Off-Highway business sale to Allison Oklo and Centrus Energy stocks jump after DoD nuclear reactor award Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data